FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808069749> ?p ?o ?g. }

• W2808069749 endingPage "1688" @default.
• W2808069749 startingPage "1673" @default.
• W2808069749 abstract "Papillary renal cell carcinoma ( PRCC ) is the most common nonclear cell RCC s and is known to comprise two histological subtypes. PRCC 2 is more aggressive and is molecularly distinct from the other subtypes. Despite this, PRCC s are treated together as one entity, and they show poor response to the current therapies that do not target pathways implicated in their pathogenesis. We have previously detected ABCC 2 (an ABC transporter), VEGF , and mTOR pathways to be enriched in PRCC 2. In this study, we assess the therapeutic potential of targeting these pathways in PRCC 2. Twenty RCC cell lines from the Cancer Cell Encyclopedia were compared to the Cancer Genome Atlas PRCC cohort (290), to identify representative PRCC 2 cell lines. Cell lines were further validated in xenograft models. Selected cell lines were treated in vitro and in vivo (mice models) under five different conditions, untreated, anti‐ VEGF (sunitinib), ABCC 2 blocker ( MK 571), mTOR inhibitor (everolimus) and sunitinib + MK 571. Sunitinib + ABCC 2 blocker group showed a significant response to therapy compared to the other treatment groups both in vitro ( P ≤ 0.0001) and in vivo ( P = 0.0132). ABCC 2 blockage resulted in higher sunitinib uptake, both in vitro ( P = 0.0016) and in vivo ( P = 0.0031). Everolimus group demonstrated the second best response in vivo . The double‐treatment group showed the highest apoptotic rate and lowest proliferation rate. There is an urgent need for individualized therapies of RCC subtypes that take into account their specific biology. Our results demonstrate that combined targeted therapy with sunitinib and ABCC 2 blocker in PRCC 2 has therapeutic potential. The results are likewise potentially significant for other ABCC 2 high tumors. However, the results are preliminary and clinical trials are needed to confirm these effects in PRCC 2 patients." @default.
• W2808069749 created "2018-06-21" @default.
• W2808069749 creator A5011364949 @default.
• W2808069749 creator A5033253453 @default.
• W2808069749 creator A5035836605 @default.
• W2808069749 creator A5038009438 @default.
• W2808069749 creator A5038476466 @default.
• W2808069749 creator A5055368367 @default.
• W2808069749 creator A5061327271 @default.
• W2808069749 creator A5061869471 @default.
• W2808069749 creator A5088388062 @default.
• W2808069749 creator A5089183368 @default.
• W2808069749 date "2018-08-23" @default.
• W2808069749 modified "2023-10-14" @default.
• W2808069749 title "Modulating <scp>ATP</scp> binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy" @default.
• W2808069749 cites W1521631645 @default.
• W2808069749 cites W1556464588 @default.
• W2808069749 cites W1591039646 @default.
• W2808069749 cites W1676375091 @default.
• W2808069749 cites W1785455093 @default.
• W2808069749 cites W1971075322 @default.
• W2808069749 cites W1975807698 @default.
• W2808069749 cites W1981140460 @default.
• W2808069749 cites W2006912785 @default.
• W2808069749 cites W2009745643 @default.
• W2808069749 cites W2015485124 @default.
• W2808069749 cites W2019413921 @default.
• W2808069749 cites W2027049002 @default.
• W2808069749 cites W2029884231 @default.
• W2808069749 cites W2030513871 @default.
• W2808069749 cites W2043398720 @default.
• W2808069749 cites W2044522508 @default.
• W2808069749 cites W2056772956 @default.
• W2808069749 cites W2072779759 @default.
• W2808069749 cites W2075093463 @default.
• W2808069749 cites W2101879059 @default.
• W2808069749 cites W2111867681 @default.
• W2808069749 cites W2118937378 @default.
• W2808069749 cites W2119884047 @default.
• W2808069749 cites W2125078979 @default.
• W2808069749 cites W2127931911 @default.
• W2808069749 cites W2132125330 @default.
• W2808069749 cites W2132570017 @default.
• W2808069749 cites W2135514225 @default.
• W2808069749 cites W2146810218 @default.
• W2808069749 cites W2149791194 @default.
• W2808069749 cites W2161000665 @default.
• W2808069749 cites W2162794726 @default.
• W2808069749 cites W2173523195 @default.
• W2808069749 cites W2233483325 @default.
• W2808069749 cites W2237908233 @default.
• W2808069749 cites W2284518822 @default.
• W2808069749 cites W2334117072 @default.
• W2808069749 cites W2512493222 @default.
• W2808069749 cites W2521607824 @default.
• W2808069749 cites W2522519290 @default.
• W2808069749 cites W2548444198 @default.
• W2808069749 cites W2565408756 @default.
• W2808069749 cites W2593824244 @default.
• W2808069749 cites W2598830924 @default.
• W2808069749 cites W2613001515 @default.
• W2808069749 cites W2624246814 @default.
• W2808069749 cites W2681483049 @default.
• W2808069749 cites W2735460229 @default.
• W2808069749 cites W2735520635 @default.
• W2808069749 cites W2740395547 @default.
• W2808069749 cites W2762272675 @default.
• W2808069749 cites W4251738294 @default.
• W2808069749 doi "https://doi.org/10.1002/1878-0261.12346" @default.
• W2808069749 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6165997" @default.
• W2808069749 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29896907" @default.
• W2808069749 hasPublicationYear "2018" @default.
• W2808069749 type Work @default.
• W2808069749 sameAs 2808069749 @default.
• W2808069749 citedByCount "11" @default.
• W2808069749 countsByYear W28080697492019 @default.
• W2808069749 countsByYear W28080697492020 @default.
• W2808069749 countsByYear W28080697492021 @default.
• W2808069749 countsByYear W28080697492022 @default.
• W2808069749 countsByYear W28080697492023 @default.
• W2808069749 crossrefType "journal-article" @default.
• W2808069749 hasAuthorship W2808069749A5011364949 @default.
• W2808069749 hasAuthorship W2808069749A5033253453 @default.
• W2808069749 hasAuthorship W2808069749A5035836605 @default.
• W2808069749 hasAuthorship W2808069749A5038009438 @default.
• W2808069749 hasAuthorship W2808069749A5038476466 @default.
• W2808069749 hasAuthorship W2808069749A5055368367 @default.
• W2808069749 hasAuthorship W2808069749A5061327271 @default.
• W2808069749 hasAuthorship W2808069749A5061869471 @default.
• W2808069749 hasAuthorship W2808069749A5088388062 @default.
• W2808069749 hasAuthorship W2808069749A5089183368 @default.
• W2808069749 hasBestOaLocation W28080697491 @default.
• W2808069749 hasConcept C121608353 @default.
• W2808069749 hasConcept C126322002 @default.
• W2808069749 hasConcept C150903083 @default.
• W2808069749 hasConcept C207001950 @default.
• W2808069749 hasConcept C2776531350 @default.
• W2808069749 hasConcept C2777472916 @default.

• next